Note: Where available, the PDF/Word icon below is provided to view the complete and fully formatted document
 Download Current HansardDownload Current Hansard    View Or Save XMLView/Save XML

Previous Fragment    Next Fragment
Monday, 21 October 2002
Page: 5573


Senator Chris Evans asked the Minister for Health and Ageing, upon notice, on 19 September 2002:

(1) What is the cost to the budget over the forward estimates period for the additional Pharmaceutical Benefits Scheme listing of Glivec for early stage chronic myeloid leukaemia announced on 10 September 2002.

(2) Was the listing of Glivec for early stage chronic myeloid leukaemia approved by Cabinet; if so, when.


Senator Patterson (Minister for Health and Ageing) —The answer to the honourable senator's question is as follows:

(1) The estimated cost to the Budget is as follows:

2002-03 $m

2003-04 $m

2004-05 $m

2005-06 $m

7.8

21.8

24.3

26.1

(2) The listing was approved by the Government in line with recommendations made by the Pharmaceutical Benefits Advisory Committee and the Pharmaceutical Benefits Pricing Authority.